Management of Pneumonia in Patients with Bronchial Asthma

Initial Assessment and Risk Stratification

The American Thoracic Society recommends assessing whether a patient with community-acquired pneumonia (CAP) can be managed outpatient versus requires hospitalization, based on the presence of asthma and other risk factors 1, 3
The Infectious Diseases Society of America suggests determining if hospital-acquired pneumonia (HAP) is early-onset (<5 days) or late-onset (≥5 days) and assessing for multidrug-resistant (MDR) pathogen risk factors 4, 5
Severity markers requiring hospitalization include tachypnea, tachycardia, hypotension, confusion, oxygen saturation requiring supplementation, or temperature >38°C, and the presence of asthma increases complication risk 1, 2

The European Respiratory Society recommends first-line treatment with amoxicillin 1g three times daily for non-severe CAP in the community, with alternative treatment being macrolides for penicillin allergy 1, 2
For hospitalized non-severe CAP, the British Thoracic Society suggests a preferred regimen of oral amoxicillin plus a macrolide 1
For severe CAP requiring ICU admission, the Society of Critical Care Medicine recommends broad-spectrum coverage with immediate initiation 6

The American Academy of Allergy, Asthma, and Immunology recommends administering aggressive bronchodilator therapy with short-acting beta-agonists for acute bronchospasm, and considering systemic corticosteroids for the asthma exacerbation component 2
The National Asthma Education and Prevention Program suggests continuing or optimizing maintenance inhaled corticosteroids for underlying asthma control 2

The American Thoracic Society recommends monitoring patients at least twice daily initially, with assessment of temperature, respiratory rate, pulse, blood pressure, mental status, and oxygen saturation 1, 8
The Infectious Diseases Society of America suggests remeasuring C-reactive protein (CRP) on days 3-4 in patients not progressing satisfactorily, with decreasing CRP indicating appropriate response 1, 8

The European Respiratory Society recommends reviewing culture results and clinical response on Days 2-3, and narrowing antibiotic spectrum based on identified pathogens and susceptibilities 5, 6
The American Thoracic Society suggests a standard duration of 7-8 days for uncomplicated pneumonia with good clinical response, with extension beyond 7 days only for persistent signs of active infection or infection with nonfermenting gram-negative bacilli 4, 6